While diabetes has been Novo’s traditional stronghold, the firm is also the front-runner to grab a big share of the rapidly-growing obesity market. A combination of changing market dynamics, including patient perspectives and innovation, has created a big obesity market opportunity, which could be worth $50bn by 2030. While Novo is likely to face competition from Eli Lilly, both firms have a clear first mover advantage. Overall, despite its expensive price tag (2022 PE of 33x), the firm’s invest ....
22 Nov 2022
The fattish obesity opportunity!
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The fattish obesity opportunity!
- Published:
22 Nov 2022 -
Author:
Abhishek Raval -
Pages:
3
While diabetes has been Novo’s traditional stronghold, the firm is also the front-runner to grab a big share of the rapidly-growing obesity market. A combination of changing market dynamics, including patient perspectives and innovation, has created a big obesity market opportunity, which could be worth $50bn by 2030. While Novo is likely to face competition from Eli Lilly, both firms have a clear first mover advantage. Overall, despite its expensive price tag (2022 PE of 33x), the firm’s invest ....